natgillin/translations-raw huggingface dataset:
The co-administration of Descovy is not recommended with certain anticonvulsants (e.g., carbamazepine, oxcarbazepine, phenobarbital and phenytoin), antimycobacterials (e.g., rifampicin, rifabutin, rifapentine), St. John's wort and HIV protease inhibitors (PIs) other than atazanavir, lopinavir and darunavir (see section 4.5). 
Ne preporučuje se istodobna primjena lijeka Descovy s određenim antikonvulzivima (npr. karbamazepinom, okskarbazepinom, fenobarbitalom i fenitoinom), antimikobakterijskim lijekovima (npr. rifampicinom, rifabutinom, rifapentinom), gospinom travom i inhibitorima proteaze HIV-a osim atazanavirom, lopinavirom i darunavirom (vidjeti dio 4.5).
No clinically relevant pharmacokinetic differences due to age, gender or ethnicity have been identified for emtricitabine, or tenofovir alafenamide. 
Klinički značajne farmakokinetičke razlike vezane uz dob, spol ili etničku pripadnost nisu ustanovljene za emtricitabin ili tenofoviralafenamid.
Dolutegravir, efavirenz, maraviroc, nevirapine, rilpivirine, raltegravir 
Descovy 200/25 mg jedanput na dan dolutegravir, efavirenz, maravirok, nevirapin, rilpivirin, raltegravir
b In both studies, patients were stratified by baseline HIV-1 RNA (≤ 100,000 copies/mL, > 100,000 copies/mL to ≤ 400,000 copies/mL, or > 400,000 copies/mL), by CD4+ cell count (< 50 cells/μL, 50-199 cells/μL, or ≥ 200 cells/μL), and by region (US or ex-US). 
b U oba ispitivanja bolesnici su stratificirani prema početnoj HIV-1 RNK (≤ 100 000 kopija/ml, > 100 000 kopija/ml do ≤ 400 000 kopija/ml, ili > 400 000 kopija/ml), prema broju CD4+ stanica (< 50 stanica/µl, 50-199 stanica/µl ili ≥ 200 stanica/µl) te po regiji (SAD ili izvan SAD-a).
• If you notice 18 hours or more after the time you usually take Descovy, then do not take the missed dose. 
• Ako to primijetite kada je prošlo 18 sati ili više od propuštene doze lijeka Descovy, onda nemojte uzeti propuštenu dozu.
The safety profile of emtricitabine and tenofovir alafenamide given with elvitegravir and cobicistat in 50 adolescent patients was similar to that in adults (see section 5.1). 
Sigurnosni profil emtricitabina i tenofoviralafenamida davanih s elvitegravirom i kobicistatom u 50 adolescentnih bolesnika bio je sličan onome u odraslih (vidjeti dio 5.1).
Tenofovir alafenamide exposure is not expected to be affected by maraviroc, nevirapine or raltegravir, nor is it expected to affect the metabolic and excretion pathways relevant to maraviroc, nevirapine or raltegravir. 
nevirapin ili raltegravir utjecati na izloženost tenofoviralafenamidu, niti se očekuje da će izloženost tenofoviralafenamidu utjecati na metaboličke puteve i puteve izlučivanja važne za maravirok, nevirapin ili raltegravir.
For monitoring of blood lipids and glucose reference is made to established HIV treatment guidelines. 
Za praćenje lipida i glukoze u krvi preporučuje se slijediti utvrđene smjernice za liječenje HIV-a.
If a patient misses a dose of Descovy by more than 18 hours, the patient should not take the missed dose and simply resume the usual dosing schedule. 
Ako je od propuštene doze prošlo više od 18 sati, bolesnik ne treba uzeti propuštenu dozu nego jednostavno nastaviti uzimati doze prema uobičajenom rasporedu.
In a study in virologically suppressed adult patients measures of tubular proteinuria were similar in patients switching to a regimen containing Descovy compared to patients who stayed on an abacavir/lamivudine containing regimen at baseline. 
U ispitivanju u odraslih bolesnika kod kojih je virus bio suprimiran, mjere tubularne proteinurije bile su slične u bolesnika prebačenih na režim koji sadrži lijek Descovy u usporedbi s bolesnicima koji su ostali na početnom režimu koji sadrži abakavir/lamivudin.
In vitro binding of tenofovir to human plasma proteins is < 0.7% and is independent of concentration over the range of 0.01-25 μg/mL. 
In vitro vezanje tenofovira za humane proteine plazme je < 0,7% i ne ovisi o koncentraciji u rasponu od 0,01-25 µg/ml.
Race Black Non-black 
Spol Muški Ženski Rasa Crnci
At Week 48, the median percentage change in urine retinol binding protein to creatinine ratio was 4% in the Descovy group and 16% in those remaining on an abacavir/lamivudine containing regimen; and in urine beta-2 microglobulin to creatinine ratio it was 4% vs. 5%. 
U 48. tjednu, medijan postotka promjene omjera proteina koji veže retinol i kreatinina u mokraći iznosio je 4% u skupini koja je primala Descovy i 16% u onih koji su ostali na režimu koji sadrži abakavir/lamivudin; a omjera beta-2 mikroglobulina i kreatinina u mokraći iznosio je 4% naspram 5%.
Tenofovir is renally eliminated by both glomerular filtration and active tubular secretion. 
Tenofovir se eliminira bubrezima i putem glomerularne filtracije i aktivne tubularne sekrecije.
Fluconazole Isavuconazole 
Flukonazol Izavukonazol
Multinucleoside-resistant HIV-1 with a T69S double insertion mutation or with a Q151M mutation complex including K65R showed reduced susceptibility to tenofovir alafenamide. 
HIV-1 rezistentan na više nukleozidnih lijekova s mutacijom dvostrukim umetanjem T69S ili kompleksom mutacija Q151M uključujući K65R pokazao je smanjenu osjetljivost na tenofoviralafenamid.
Assessment of adverse reactions is based on safety data from across all Phase 2 and 3 studies in which 3,112 HIV-1 infected patients received medicinal products containing emtricitabine and tenofovir alafenamide and from post-marketing experience. 
Procjena nuspojava temelji se na podacima o sigurnosti iz svih ispitivanja faze 2 i 3 u kojima je 3112 bolesnika zaraženih virusom HIV-1 primalo lijekove koji sadrže emtricitabin i tenofoviralafenamid te iz razdoblja nakon stavljanja u promet.
EU/1/16/1099/001 EU/1/16/1099/002 
EU/1/16/1099/002
Baseline viral load ≤ 100,000 copies/mL > 100,000 copies/mL 
≤ 100 000 kopija/ml > 100 000 kopija/ml
Descovy 200 mg/10 mg [Outer packaging only] 
Descovy 200 mg/10 mg [samo vanjsko pakiranje]
In animal studies there were no effects of emtricitabine and tenofovir alafenamide on mating or fertility parameters (see section 5.3). 
U ispitivanjima na životinjama nije bilo učinaka emtricitabina i tenofoviralafenamida na parenje ili parametre plodnosti (vidjeti dio 5.3).
Emtricitabine systemic exposure was unaffected when emtricitabine was administered with food. 
Primjena emtricitabina s hranom nije utjecala na sistemsku izloženost emtricitabinu.
The frequencies were derived from Phase 3 E/C/F/TAF clinical studies in 866 treatment-naïve adult patients through 144 weeks of treatment (GS-US-292-0104 and GS-US-292-0111). 
Učestalosti su izvedene iz podataka faze 3 kliničkih ispitivanja E/C/F/TAF-a tijekom 144 tjedna liječenja 866 odraslih bolesnika koji prethodno nisu bili liječeni (GS-US-292-0104 i GS-US-292-0111).
The recommended dose of Descovy is 200/10 mg once daily. 
Preporučena doza lijeka Descovy je 200/10 mg jedanput na dan.
a n = 24 adolescents (GS-US-292-0106); n = 19 adults (GS-US-292-0102) b n = 23 adolescents (GS-US-292-0106, population PK analysis) c n = 539 (TAF) or 841 (TFV) adults (GS-US-292-0111 and GS-US-292-0104, population PK analysis) 
Podaci su prikazani kao srednja vrijednost (% CV) a n = 24 adolescenta (GS-US-292-0106); n = 19 odraslih (GS-US-292-0102) b n = 23 adolescenta (GS-US-292-0106, populacijska farmakokinetička analiza) c n = 539 (TAF) ili 841 (TFV) odraslih (GS-US-292-0111 i GS-US-292-0104, populacijska farmakokinetička analiza)
The recommended dose of Descovy is 200/25 mg once daily. 
Preporučena doza lijeka Descovy je 200/25 mg jedanput na dan.
If you vomit less than 1 hour after taking Descovy, take another tablet. 
Ako povratite unutar 1 sata od uzimanja lijeka Descovy, uzmite drugu tabletu.
2 This adverse reaction was not observed in the clinical studies of F/TAF-containing products but identified from clinical studies or post-marketing experience for emtricitabine when used with other antiretrovirals. 
Ova nuspojava nije uočena u kliničkim ispitivanjima lijekova koji sadrže F/TAF, ali je prepoznata u kliničkim ispitivanjima emtricitabina ili tijekom praćenja emtricitabina nakon stavljanja u promet kad se koristio s drugim antiretrovirusnim lijekovima.
ANTI-INFECTIVES Antifungals Ketoconazole Itraconazole 
Antimikotici Ketokonazol Itrakonazol
Descovy should generally be avoided but may be used in adults with end stage renal disease (estimated CrCl < 15 mL/min) on chronic haemodialysis if the potential benefits outweigh the potential risks (see section 4.2). 
Iako Descovy općenito treba izbjegavati u odraslih sa završnim stadijem bolesti bubrega (procijenjeni CrCl < 15 ml/min) na kroničnoj hemodijalizi, može ga se primijeniti ako se smatra da su moguće koristi veće od mogućih rizika (vidjeti dio 4.2).
The pharmacokinetics of emtricitabine and tenofovir alafenamide have not been fully evaluated in patients co-infected with HBV and/or HCV. 
Farmakokinetika emtricitabina i tenofoviralafenamida nije potpuno procijenjena u bolesnika koji su istodobno zaraženi HBV-om i/ili HCV-om.
Most HIV-1 isolates from patients in both treatment groups who developed resistance mutations to elvitegravir in integrase also developed resistance mutations to emtricitabine in RT. 
Većina HIV-1 izolata od bolesnika iz obje skupine koji su razvili mutacije u integrazi povezane s rezistencijom na elvitegravir, razvili su i mutacije u RT-u povezane s rezistencijom na emtricitabin.
Patients were randomised in a 1:1 ratio to either switch to Descovy (n = 333), or stay on their baseline emtricitabine/tenofovir disoproxil fumarate containing regimen (n = 330). 
Bolesnici su bili randomizirani u omjeru 1:1 kako bi se prebacili bilo na lijek Descovy (n = 333) ili ostali na svom početnom režimu koji sadrži emtricitabin/tenofovirdizoproksilfumarat (n = 330).
Emtricitabine is rapidly and extensively absorbed following oral administration with peak plasma concentrations occurring at 1 to 2 hours post-dose. 
Nakon peroralne primjene, emtricitabin se brzo i opsežno apsorbira i postiže vršne koncentracije u plazmi 1-2 sata nakon doziranja.
Descovy should be avoided in antiretroviral-experienced patients with HIV-1 harbouring the K65R mutation (see section 5.1). 
Descovy treba izbjegavati u bolesnika čiji HIV-1 nosi mutaciju K65R, a prethodno su liječeni antiretrovirusnim lijekovima (vidjeti dio 5.1).
Tenofovir diphosphate inhibits HIV replication through incorporation into viral DNA by the HIV RT, which results in DNA chaintermination. 
Tenofovirdifosfat inhibira replikaciju HIV-a ugradnjom u virusnu DNK pomoću HIV RT što dovodi do prekida lanca DNK.
No dose adjustment of sofosbuvir, velpatasvir or voxilaprevir is required. 
Nije potrebna prilagodba doze sofosbuvira, velpatasvira ili voksilaprevira.
Table 3: Tabulated list of adverse reactions1 
Tablica 3: Tablični prikaz nuspojava1
< 20 copies/mL 
< 50 kopija/mle
In HIV infected patients with severe immune deficiency at the time of institution of CART, an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. 
U bolesnika zaraženih HIV-om s teškom imunodeficijencijom u vrijeme uvođenja CART-a može doći do upalne reakcije na asimptomatske ili rezidualne oportunističke patogene, koja može uzrokovati teška klinička stanja ili pogoršanje simptoma.
Descovy 200 mg/25 mg [Outer packaging only] 
Descovy 200 mg/25 mg [samo vanjsko pakiranje]
If the patient misses a dose of Descovy within 18 hours of the time it is usually taken, the patient should take Descovy as soon as possible and resume the normal dosing schedule. 
Ako je bolesnik propustio uzeti dozu lijeka Descovy, a sjetio se unutar 18 sati od propuštene doze, bolesnik mora što prije uzeti lijek Descovy i potom ga nastaviti uzimati prema uobičajenom rasporedu.
• If you notice within 18 hours of the time you usually take Descovy, you must take the tablet as soon as possible. 
• Ako to primijetite unutar 18 sati od propuštene doze lijeka Descovy, tabletu morate uzeti što prije.
EU/1/16/1099/003 EU/1/16/1099/004 
EU/1/16/1099/004
Studies of tenofovir alafenamide in animals have shown no evidence of harmful effects on fertility parameters, pregnancy, or foetal development (see section 5.3). 
Ispitivanja tenofoviralafenamida na životinjama nisu pokazala nikakve dokaze štetnih učinaka na parametre plodnosti, trudnoću ili razvoj fetusa (vidjeti dio 5.3).
Co-administration of Descovy with other medicinal products that inhibit P-gp and BCRP activity (e.g., cobicistat, ritonavir, ciclosporin) is expected to increase the absorption and plasma concentration of tenofovir alafenamide. 
Očekuje se da će istodobna primjena lijeka Descovy s drugim lijekovima koji inhibiraju aktivnost P-gp-a i BCRP-a (npr. kobicistat, ritonavir, ciklosporin) povećati apsorpciju i koncentraciju tenofoviralafenamida u plazmi.
Treatment outcomes of Study GS-US-311-1089 through 48 and 96 weeks are presented in Table 6. 
Ishodi liječenja u Ispitivanju GS-US-311-1089 do kraja 48. i 96. tjedna prikazani su u Tablici 6.
The median (Q1, Q3) change from baseline in total cholesterol to HDL-cholesterol ratio at Week 144 was 0.2 (-0.3, 0.7) in the E/C/F/TAF group and 0.1 (-0.4, 0.6) in the E/C/F/TDF group (p = 0.006 for the difference between treatment groups). 
Medijan (Q1, Q3) promjene omjera ukupnog kolesterola i HDL kolesterola od početne vrijednosti do vrijednosti u 144. tjednu bio je 0,2 (-0,3; 0,7) u skupini liječenoj E/C/F/TAFom i 0,1 (-0,4; 0,6) u skupini liječenoj E/C/F/TDF-om (p = 0,006 za razliku između liječenih skupina).
While you are taking Descovy 
Dok uzimate lijek Descovy
Descovy should be discontinued in patients with estimated CrCl that declines below 30 mL/min during treatment (see section 5.2). 
Potrebno je prekinuti liječenje lijekom Descovy u bolesnika u kojih procijenjeni CrCl tijekom liječenja opada na vrijednosti ispod 30 ml/min (vidjeti dio 5.2).
The antiviral activity of emtricitabine against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cell lines, the MAGI CCR5 cell line, and PBMCs. 
Antivirusno djelovanje emtricitabina na laboratorijske i kliničke izolate virusa HIV-1 procijenjeno je na limfoblastoidnim staničnim linijama, staničnoj liniji MAGI CCR5 i PBMC-ovima.
At 48 weeks, 92% (46/50) achieved HIV-1 RNA < 50 copies/mL, similar to response rates in studies of treatment-naïve HIV-1 infected adults. 
U 48. tjednu, njih 92% (46/50) postiglo je HIV-1 RNK < 50 kopija/ml, što je slično stopama odgovora u ispitivanjima odraslih bolesnika zaraženih virusom HIV-1 koji prethodno nisu bili liječeni.
In a study of virologically suppressed adult patients switching from abacavir/lamivudine to Descovy while maintaining the third antiretroviral agent (Study GS-US-311-1717), there were minimal changes in lipid parameters. 
U ispitivanju u odraslih bolesnika kod kojih je virus bio suprimiran i koji su prebačeni s režima abakavir/lamivudin na lijek Descovy uz zadržavanje liječenja trećim antiretrovirusnim lijekom (Ispitivanje GS-US-311-1717) promjene u lipidnim parametrima bile su minimalne.
Table 1: Dose of Descovy according to third agent in the HIV treatment regimen 
Tablica 1: Doza lijeka Descovy ovisno o trećem lijeku u režimu liječenja HIV-a
D/C/F/TAF = darunavir/cobicistat/emtricitabine/tenofovir alafenamide a Week 48 window was between Day 294 and 377 (inclusive). 
D/C/F/TAF = darunavir/kobicistat/emtricitabin/tenofoviralafenamid a Okvir 48. tjedna bio je između 294. i 377. dana (uključivo).
At baseline, 30% of patients were receiving abacavir/lamivudine in combination with a boosted protease inhibitor and 70% of patients were receiving abacavir/lamivudine in combination with an unboosted third agent. 
Na početku je 30% bolesnika primalo abakavir/lamivudin u kombinaciji s pojačanim inhibitorom proteaze, a 70% bolesnika primalo je abakavir/lamivudin u kombinaciji s nepojačanim trećim lijekom.
EU/1/16/1099/001 30 film-coated tablets EU/1/16/1099/002 90 (3 bottles of 30) film-coated tablets 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/16/1099/001 30 filmom obloženih tableta EU/1/16/1099/002 90 (3 boce od 30) filmom obloženih tableta
A minimal infiltration of histiocytes was present in the eye in dogs at tenofovir alafenamide and tenofovir exposures of approximately 4 and 17 times greater, respectively, than those expected after administration of Descovy. 
U oku pasa bila je prisutna minimalna infiltracija histiocitima kod izloženosti tenofoviralafenamidu i tenofoviru koja je bila približno 4 odnosno 17 puta veća od one očekivane nakon primjene lijeka Descovy.
At the start of treatment with E/C/F/TAF, the 72 patients had been HIV-suppressed (HIV-1 RNA < 50 copies/mL) for at least 6 months with or without suppression of HBV DNA and had compensated liver function. 
Na početku liječenja E/C/F/TAF-om, 72 bolesnika imali su supresiju HIV-a (HIV-1 RNK < 50 kopija/ml) najmanje 6 mjeseci sa ili bez supresije HBV DNA i imali su kompenziranu funkciju jetre.
EU/1/16/1099/003 30 film-coated tablets EU/1/16/1099/004 90 (3 bottles of 30) film-coated tablets 
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/16/1099/003 30 filmom obloženih tableta EU/1/16/1099/004 90 (3 boce od 30) filmom obloženih tableta
In a separate Phase 1 study of emtricitabine alone, mean systemic emtricitabine exposure was higher in patients with severe renal impairment (estimated CrCl < 30 mL/min) (33.7 μg•h/mL) than in subjects with normal renal function (11.8 μg•h/mL). 
U zasebnom ispitivanju faze I u kojem se ispitivao samo emtricitabin, srednja vrijednost sistemske izloženosti emtricitabinu bila je viša u bolesnika s teškim oštećenjem funkcije bubrega (procijenjeni CrCl < 30 ml/min) (33,7 µg•h/ml) nego u ispitanika s normalnom funkcijom bubrega (11,8 µg•h/ml).
Emtricitabine displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, and G (EC50 values ranged from 0.007 to 0.075 μM) and showed strain specific activity against HIV-2 (EC50 values ranged from 0.007 to 1.5 μM). 
Emtricitabin je pokazao antivirusnu aktivnost u staničnoj kulturi na podtipove virusa HIV-1 A, B, C, D, E, F i G (vrijednosti EC50 bile su u rasponu od 0,007 do 0,075 µM) i specifičnu aktivnost na sojeve virusa HIV-2 (vrijednosti EC50 bile su u rasponu od 0,007 do 1,5 µM).
Following multiple dose oral administration of emtricitabine to 20 HIV-1 infected subjects, the (mean ± SD) steady state plasma emtricitabine peak concentrations (Cmax) were 1.8 ± 0.7 μg/mL and the area-under the plasma concentration-time curve over a 24-hour dosing interval (AUC) was 10.0 ± 3.1 μg•h/mL. 
Nakon peroralne primjene višestruke doze emtricitabina u 20 ispitanika zaraženih virusom HIV-1, vršne koncentracije (Cmax) (srednja vrijednost ± SD) emtricitabina u plazmi pri dinamičkoj ravnoteži bile su 1,8 ± 0,7 µg/ml, a površina ispod krivulje koncentracija-vrijeme tijekom 24-satnog intervala doziranja (AUC) bila je 10,0 ± 3,1 µg•h/ml.
Co-administration of Descovy and rifabutin rifampicin, or rifapentine is not recommended. 
Ne preporučuje se istodobna primjena lijeka Descovy i rifabutina, rifampicina ili rifapentina.
If the patient vomits within 1 hour of taking Descovy another tablet should be taken. 
Ako bolesnik povraća unutar 1 sata od uzimanja lijeka Descovy, mora uzeti drugu tabletu.
E/C/F/TAF = elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide E/C/F/TDF = elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate a Week 48 window was between Day 294 and 377 (inclusive); Week 144 window was between Day 966 and 1049 (inclusive). 
E/C/F/TAF = elvitegravir/kobicistat/emtricitabin/tenofoviralafenamid E/C/F/TDF = elvitegravir/kobicistat/emtricitabin/tenofovirdizoproksilfumarat a Okvir 48. tjedna bio je između 294. i 377. dana (uključivo); Okvir 144. tjedna bio je između 966. i 1049. dana (uključivo).
 If any of the side effects get serious tell your doctor. 
Ako neka od ovih nuspojava postane ozbiljna, obavijestite svog liječnika.
Following administration of food in healthy subjects, peak plasma concentrations were observed approximately 1 hour post-dose for tenofovir alafenamide administered as F/TAF (25 mg) or E/C/F/TAF (10 mg). 
Nakon primjene hrane u zdravih ispitanika, vršne koncentracije tenofoviralafenamida u plazmi, primijenjenog kao F/TAF (25 mg) ili E/C/F/TAF (10 mg), bile su opažene približno 1 sat nakon doziranja.
Co-administration of ketoconazole or itraconazole, which are potent P-gp inhibitors, is expected to increase plasma concentrations of tenofovir alafenamide. 
Očekuje se da će istodobna primjena ketokonazola ili itrakonazola, koji su jaki inhibitori P-gp-a, povisiti koncentracije tenofoviralafenamida u plazmi.
The mean baseline plasma HIV-1 RNA was 4.5 log10 copies/mL (range: 1.3-7.0) and 23% had baseline viral loads > 100,000 copies/mL. 
Srednja početna vrijednost HIV-1 RNK u plazmi bila je 4,5 log10 kopija/ml (raspon: 1,3-7,0), a 23% imalo je početno virusno opterećenje > 100 000 kopija/ml.
Film-coating: Polyvinyl alcohol, titanium dioxide, macrogol 3350, talc, iron oxide black (E172). 
Poli(vinilni alkohol), titanijev dioksid, makrogol 3350, talk, željezov oksid, crni (E172)
Patients must have been stably suppressed (HIV-1 RNA < 50 copies/mL) on their baseline regimen for at least 6 months and had HIV-1 with no resistance mutations to emtricitabine or tenofovir alafenamide prior to study entry. 
U bolesnika je HIV-1 morao biti stabilno suprimiran (HIV-1 RNK < 50 kopija/ml) početnim režimom najmanje 6 mjeseci i biti bez mutacija povezanih s rezistencijom na emtricitabin ili tenofoviralafenamid prije ulaska u ispitivanje.
The safety of emtricitabine and tenofovir alafenamide has not been established in patients with severe renal impairment (estimated CrCl ≥ 15 mL/min and < 30 mL/min). 
Sigurnost emtricitabina i tenofoviralafenamida nije ustanovljena u bolesnika s teškim oštećenjem funkcije bubrega (procijenjeni CrCl ≥ 15 ml/min i < 30 ml/min).
High density polyethylene (HDPE) bottle with a polypropylene continuous-thread, child-resistant cap, lined with an induction activated aluminium foil liner containing 30 film-coated tablets. 
Boca od polietilena visoke gustoće (HDPE) s polipropilenskim sigurnosnim zatvaračem za djecu s kontinuiranim navojem, otvora prekrivenog zaštitnom aluminijskom folijom, koja sadrži 30 filmom obloženih tableta.
Emtricitabine triphosphate inhibits HIV replication through incorporation into viral deoxyribonucleic acid (DNA) by the HIV reverse transcriptase (RT), which results in DNA chaintermination. 
Emtricitabin trifosfat inhibira replikaciju HIV-a ugradnjom u virusnu deoksiribonukleinsku kiselinu (DNK) pomoću reverzne transkriptaze (RT) što dovodi do prekida lanca DNK.
Based on data from an in vitro study, co-administration of tenofovir alafenamide and xanthine oxidase inhibitors (e.g., febuxostat) is not expected to increase systemic exposure to tenofovir in vivo. 
Na temelju podataka in vitro ispitivanja, ne očekuje se da će istodobna primjena tenofoviralafenamida i inhibitora ksantin oksidaze (npr. febuksostata) povećati sistemsku izloženost tenofoviru in vivo.
Patients had a mean age of 15 years (range: 12-17), and 56% were female, 12% were Asian, and 88% were Black. 
Bolesnici su imali srednju vrijednost dobi 15 godina (raspon: 12-17), a 56% bile su djevojke, 12% azijati i 88% crnci.
There are no or limited data (less than 300 pregnancy outcomes) from the use of tenofovir alafenamide in pregnant women. 
Nema podataka ili su podaci o primjeni tenofoviralafenamida u trudnica ograničeni (manje od 300 trudnoća).
Patients were virologically suppressed (HIV-1 RNA < 50 copies/mL) for at least 6 months before switching. 
U bolesnika je virus bio suprimiran (HIV-1 RNK < 50 kopija/ml) tijekom najmanje 6 mjeseci prije prebacivanja.
In Study GS-US-299-0102, patients were randomised in a 2:1 ratio to receive either fixed-dose combination D/C/F/TAF once daily (n = 103) or darunavir and cobicistat and emtricitabine/tenofovir disoproxil fumarate once daily (n = 50). 
U Ispitivanju GS-US-299-0102, bolesnici su bili randomizirani u omjeru 2:1 kako bi primali fiksnu kombinaciju D/C/F/TAF jednom dnevno (n = 103) ili darunavir, kobicistat i emtricitabin/tenofovirdizoproksilfumarat jednom dnevno (n = 50).